Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL or ALL
Background: T lymphocyte collection through leukapheresis is an essential step for chimeric antigen receptor T (CAR-T) cell therapy. Timing of apheresis is challenging in heavily pretreated patients who suffer from rapid progressive disease and receive T cell impairing medication. Methods: A total o...
保存先:
| 主要な著者: | , , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
MDPI AG
2020-05-01
|
| シリーズ: | Cells |
| 主題: | |
| オンライン・アクセス: | https://www.mdpi.com/2073-4409/9/5/1225 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|
